title: Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma.
authors.affiliation: Washington University School of Medicine, St Louis, Missouri.
authors.forename: Rachel L
authors.initials: RL
authors.lastname: Kyllo
authors.affiliation: Division of Dermatology, Washington University, St Louis, Missouri.
authors.forename: Mary Kendall
authors.initials: MK
authors.lastname: Parker
authors.affiliation: Division of Dermatology and Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.
authors.forename: Ilana
authors.initials: I
authors.lastname: Rosman
authors.affiliation: Division of Dermatology, Washington University, St Louis, Missouri. Electronic address: amusiek@dom.wustl.edu.
authors.forename: Amy C
authors.initials: AC
authors.lastname: Musiek
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001707:Biopsy, Needle; D017024:Chemotherapy, Adjuvant; D003622:Dapsone / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011241:Prednisone / Q000627:therapeutic use; D018570:Risk Assessment; D012720:Severity of Illness Index; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016463:Sweet Syndrome / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D003622:Dapsone; D011241:Prednisone